NCCN on molecular profiling in bladder cancer – pro
Molecular profiling refers to testing for various targets that may be present in a specific cancer in specific patient and then using therapy targeted to those targets, irrespective of data on effectiveness in the tumor type. NCCN recognized this approach for bladder cancer, and bladder cancer only in late 2016 and for lung in 2017. Management of advanced bladder cancer represents a sharp contrast to the more sophisticated approach to breast and lung cancer. The current algorithm for the management of bladder cancer is a rather dichotomous decision of cisplatin or no cisplatin. whereas in breast cancer there are many options for each line of therapy. Therefore, one cannot generalize that NCCN approved molecular testing in any cancer other than bladder and lung, but not neuroendcrine cancer at this time.
Sumanta Kumar Pal, National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. Clinical Oncology 34, no. 27 (September 2016) 3346-3348.
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.J, Breast Cancer Version 2.2015. Natl Compr Canc Netw. 2015 Apr;13(4):448-75.